title: Detection of novel amplicons in prostate cancer by comprehensive genomic profiling of prostate cancer cell lines using oligonucleotide-based arrayCGH.
abstract: BACKGROUND
  The purpose of this study was to prove the feasibility of a longmer oligonucleotide microarray platform to profile gene copy number alterations in prostate cancer cell lines and to quickly indicate novel candidate genes, which may play a role in carcinogenesis.
  Genome-wide screening for regions of genetic gains and losses on nine prostate cancer cell lines (PC3, DU145, LNCaP, CWR22, and derived sublines) was carried out using comparative genomic hybridization on a 35,000 feature oligonucleotide microarray (arrayCGH). Compared to conventional chromosomal CGH, more deletions and small regions of gains, particularly in pericentromeric regions and regions next to the telomeres, were detected. As validation of the high-resolution of arrayCGH we further analyzed a small amplicon of 1.7 MB at 9p13.3, which was found in CWR22 and CWR22-Rv1. Increased copy number was confirmed by fluorescence in situ hybridization using the BAC clone RP11-165H19 from the amplified region comprising the two genes interleukin 11 receptor alpha (IL11-RA) and dynactin 3 (DCTN3). Using quantitative real time PCR (qPCR) we could demonstrate that IL11-RA is the gene with the highest copy number gain in the cell lines compared to DCTN3 suggesting IL11-RA to be the amplification target. Screening of 20 primary prostate carcinomas by qPCR revealed an IL11-RA copy number gain in 75% of the tumors analyzed. Gain of DCTN3 was only found in two cases together with a gain of IL11-RA.
  
  
  CONCLUSIONS
  ArrayCGH using longmer oligonucleotide microarrays is feasible for high-resolution analysis of chomosomal imbalances. Characterization of a small gained region at 9p13.3 in prostate cancer cell lines and primary prostate cancer samples by fluorescence in situ hybridization and quantitative PCR has revealed interleukin 11 receptor alpha gene as a candidate target of amplification with an amplification frequency of 75% in prostate carcinomas. Frequent amplification of IL11-RA in prostate cancer is a potential mechanism of IL11-RA overexpression in this tumor type.
authors: Department of Urology and Pediatric Urology, University of Saarland, Homburg/Saar, Germany. joern.kamradt@uks.eu
authors: Joern
authors: J
authors: Kamradt
authors: Volker
authors: V
authors: Jung
authors: Kerstin
authors: K
authors: Wahrheit
authors: Laura
authors: L
authors: Tolosi
authors: Joerg
authors: J
authors: Rahnenfuehrer
authors: Martin
authors: M
authors: Schilling
authors: Robert
authors: R
authors: Walker
authors: Sean
authors: S
authors: Davis
authors: Michael
authors: M
authors: Stoeckle
authors: Paul
authors: P
authors: Meltzer
authors: Bernd
authors: B
authors: Wullich
mesh_terms: D045744:Cell Line, Tumor; D002877:Chromosomes, Human; D055028:Comparative Genomic Hybridization / Q000379:methods*; D056915:DNA Copy Number Variations; D020869:Gene Expression Profiling / Q000379:methods*; D015972:Gene Expression Regulation, Neoplastic; D020022:Genetic Predisposition to Disease; D015894:Genome, Human; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D008297:Male; D020411:Oligonucleotide Array Sequence Analysis / Q000379:methods*; D011471:Prostatic Neoplasms / Q000235:genetics*
references: Proc Natl Acad Sci U S A. 2004 Dec 21;101(51):17765-70
references: 15591353
references: Int J Cancer. 2006 Sep 15;119(6):1322-9
references: 16642477
references: Nat Genet. 1998 Oct;20(2):207-11
references: 9771718
references: Genes Chromosomes Cancer. 2004 Mar;39(3):171-84
references: 14732919
references: Prostate. 2004 Apr 1;59(1):43-58
references: 14991865
references: Cancer Res. 2004 Jul 15;64(14):4744-8
references: 15256441
references: Genes Chromosomes Cancer. 2004 Mar;39(3):249-56
references: 14732926
references: Genes Chromosomes Cancer. 1997 Dec;20(4):399-407
references: 9408757
references: J Biomed Opt. 1997 Oct;2(4):364-74
references: 23014960
references: Am J Pathol. 2003 Mar;162(3):763-70
references: 12598311
references: Genome Res. 2003 May;13(5):954-64
references: 12695328
references: Nat Genet. 2003 Aug;34(4):369-76
references: 12923544
references: J Neuropathol Exp Neurol. 1999 Sep;58(9):993-9
references: 10499441
references: Prostate. 1997 May 15;31(3):168-74
references: 9167768
references: Bioinformatics. 2005 May 15;21(10):2438-46
references: 15705654
references: Genome Biol. 2004;5(10):R80
references: 15461798
references: Cancer Res. 2004 Jan 15;64(2):435-9
references: 14744752
references: Cancer Genet Cytogenet. 2004 Apr 15;150(2):122-7
references: 15066319
references: Prostate. 1999 May;39(2):79-86
references: 10221562
references: Int J Oncol. 2002 Oct;21(4):695-706
references: 12239607
references: Oncogene. 2003 Feb 27;22(8):1247-52
references: 12606952
references: Am J Pathol. 2001 Jan;158(1):25-32
references: 11141475
references: Bioinformatics. 2004 Dec 12;20(18):3413-22
references: 15381628
references: Clin Chem. 2005 Mar;51(3):649-52
references: 15738520
references: Mol Cancer Res. 2006 Mar;4(3):169-76
references: 16547154
references: Prostate. 2005 May 1;63(2):187-97
references: 15486987
references: Blood. 1995 Aug 15;86(4):1243-54
references: 7632928
references: Science. 1992 Oct 30;258(5083):818-21
references: 1359641
references: BJU Int. 2005 Jun;95(9):1320-6
references: 15892825
references: Nat Genet. 1999 Sep;23(1):41-6
references: 10471496
references: Neoplasia. 2004 May-Jun;6(3):240-7
references: 15153336
references: Clin Cancer Res. 2005 Sep 1;11(17):6333-41
references: 16144938
references: Cancer Genet Cytogenet. 2001 Jan 15;124(2):98-104
references: 11172899